Pathology & Oncology Research

, Volume 16, Issue 1, pp 55–59 | Cite as

Comparison of Osteopontin, β-catenin and hnRNP B1 Expression in Lung Carcinomas

  • Muhammet Emin Guldur
  • Yasemin Kıbar
  • Hale Denız
  • Kemal Bakır


This study was performed to compare osteopontin (OPN), β-catenin and heterogeneous nuclear ribonucleoprotein B1 (hnRNP B1) immunreactivities in small cell lung carcinomas (SCLC) and non-small cell lung carcinomas (NSCLC). Correlation of these three antibodies with grade and clinicopathologic stage of the tumor in NSCLC was also investigated. Twenty-nine SCLC, 6 large cell carcinoma, 36 adenocarcinoma and 30 squamous cell carcinoma (SCC), totally 101 cases, were included in this study. OPN, β-catenin and hnRNP B1 expressions were immunohistochemically evaluated. OPN positivity was 6.9% in SCLC and 67% in NSCLC. When NSCLC types were individually considered, OPN positivity was 66.7% in large cell carcinoma, 80% in SCC and 55.6% in adenocarcinomas. β-catenin positivity was observed in 48.6% of NSCLC and none of SCLC cases. These results were statistically significant (p < 0.05). Neither grade nor stage of NSCLC was correlated with osteopontin, β-catenin or hnRNP B1 immunreactivity. We observed that OPN and β-catenin are useful in differentiating SCLC from NSCLC. This may be helpful in small lung biopsies where morphology is obscured by crush artifacts.


Osteopontin Beta-catenin Heterogeneous nuclear ribonucleoprotein B1 Lung cancer 



We thank Huseyin Kizilirmak for his skillful technical assistance and Dr. Neriman Aydin for her expert statistical analyses.


  1. 1.
    Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190CrossRefPubMedGoogle Scholar
  2. 2.
    Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459–6465CrossRefPubMedGoogle Scholar
  3. 3.
    Nozawa N, Hashimoto S, Nakashima Y, Matsuo Y, Koga T, Sugio K, Niho Y, Harada M, Sueishi K et al (2006) Immunohistochemical α and β-catenin and E-cadherin expression and their clinocopathological significance in human lung adenocarcinoma. Pathol Res Pract 202:639–650CrossRefPubMedGoogle Scholar
  4. 4.
    Prinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM (2001) Reduced expression of α-catenin, β-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 54:391–395CrossRefGoogle Scholar
  5. 5.
    Sueoka E, Sueoka N, Goto Y, Matsuyama S, Nishimura H, Sato M, Fujimura S, Chiba H, Fujiki H (2001) Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res 61:1896–1902PubMedGoogle Scholar
  6. 6.
    Zhou J, Mulshine JL, Unsworth EJ, Scott FM, Avis IM, Vos MD, Treston AM (1996) Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J Biol Chem 271:10760–10766CrossRefPubMedGoogle Scholar
  7. 7.
    Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K, Fukuchi Y (2001) Differential osteopontin expression in lung cancer. Cancer Lett 171:215–222CrossRefPubMedGoogle Scholar
  8. 8.
    Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11:4646–4652CrossRefPubMedGoogle Scholar
  9. 9.
    Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K (2000) Expression of E-cadherin and β-Catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6:4789–4796PubMedGoogle Scholar
  10. 10.
    Wu S, Sato M, Endo C, Sakurada A, Dong B, Aikawa H, Chen Y, Okada Y, Matsumura Y, Sueoka E, Kondo T (2003) HnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. Lung Cancer 41:179–186CrossRefPubMedGoogle Scholar
  11. 11.
    Zech VF, Dlaska M, Tzankov A, Hilbe W (2006) Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 in non- small cell lung cancer. Cancer Detect Prev 30:395–402CrossRefPubMedGoogle Scholar
  12. 12.
    Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH, Danenberg PV (2004) Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 10:1588–1596CrossRefPubMedGoogle Scholar
  13. 13.
    Choi YS, Shim YM, Kim SH, Son DS, Lee HS, Kim GY, Han J, Kim J (2003) Prognostic significance of E-cadherin and β-catenin in resected stage 1 non-small cell lung cancer. Eur J Cardiothorac Surg 24:441–449CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2009

Authors and Affiliations

  • Muhammet Emin Guldur
    • 1
  • Yasemin Kıbar
    • 2
  • Hale Denız
    • 3
  • Kemal Bakır
    • 4
  1. 1.Department of PathologyHarran University Faculty of MedicineSanliurfaTurkey
  2. 2.Department of PathologySehitkamil HospitalGaziantepTurkey
  3. 3.Gaziantep Children HospitalDepartment of PathologyGaziantepTurkey
  4. 4.Department of PathologyGaziantep University Faculty of MedicineGaziantepTurkey

Personalised recommendations